NDLI: Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA).

Please wait, while we are loading the content...

Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA).

Increased sympathetic modulation and decreased response of the heart rate variability in controlled asthma.

Urbanization factors associated with childhood asthma and prematurity: a population-based analysis aged from 0 to 5 years in Taiwan by using Cox regression within a hospital cluster model.

UGT1A1*28 is associated with greater decrease in serum Kâº levels following oral intake of procaterol.

The development and test re-test reliability of a work-related asthma screening questionnaire.

Complementary and alternative medicine use among people with asthma and health-related quality of life.

Evaluation of Th17-related cytokines and IFNÎ³ production from blood mononuclear cells of moderate and severe asthmatic children reveals methylprednisolone does not decrease IL-22 levels.

Evaluation of asthma control, parents' quality of life and preference between AeroChamber Plus and AeroChamber Plus Flow-Vu spacers in young children with asthma.

Validation of a questionnaire against clinical assessment in the diagnosis of asthma in school children.

SPINK5 and ADRB2 haplotypes are risk factors for asthma in Mexican pediatric patients.

Asthma education: different viewpoints elicited by qualitative and quantitative methods.

Dry mouth as a novel indicator of hoarseness caused by inhalation therapy.

A perspective on point-of-care tests to detect eosinophilic bronchitis.

Year: 2015 Volume: 52 Issue: 2

Year: 2015 Volume: 52 Issue: 1

Year: 2014 Volume: 51

Year: 2013 Volume: 50

Year: 2012 Volume: 49

Year: 2011 Volume: 48

Year: 2010 Volume: 47

Year: 2009 Volume: 46

Year: 2008 Volume: 45

Year: 2007 Volume: 44

Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA).

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Chishimba, Livingstone Langridge, Philip Powell, Georgina Niven, Robert M. Denning, David W.
Description	Country affiliation: United kingdom Author Affiliation: Chishimba L ( Manchester Academic Health Science Centre, University Hospital South Manchester NHS Foundation Trust, The University of Manchester , Manchester , UK .)
Abstract	BACKGROUND AND RATIONALE: Antifungal therapy for severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) remains poorly studied. We assessed the efficacy and safety of NAB as second and third line therapy in SAFS and ABPA. METHODS: 21 adult asthmatics with SAFS (n = 11) and ABPA (n = 10) who had either failed itraconazole (n = 8), voriconazole proceeded by itraconazole (n = 5) or developed adverse events (AEs) to either agent (n = 7) were treated with 10mg of NAB (Fungizone) twice daily. We audited clinical and immunological response, using the Asthma Quality of Life Questionnaire (AQLQ-J) scores, asthma control, FEV1, healthcare utilisation and IgE. Patients were followed up for 12 months. RESULTS: Twenty-one patients were treated (SAFS, n = 11) and (ABPA, n = 10), M: F = 8:12, median age 65 years (range, 24-78). The median duration of therapy was 30 days (0-1825). Clinical benefit was observed in three (14.3 %) in which overall mean AQLQ-J score improved by + 2.9, mean FEV1 improved by 0.5 L and there was improvement in overall asthma control. Seven (33%) failed initial dose (bronchospasm). Eleven (52.4%) discontinued within 12 months of therapy due to delayed bronchospasm (n = 3, within 4 weeks), equipment problems (n = 2, within 4 weeks) and lack of clinical benefit (n = 4, within 16 weeks). CONCLUSION: Our data suggest that the overall efficacy of NAB in this group of patients is poor and associated with bronchospasm. However, the excellent response in 3 patients, suggest it may be considered when other alternatives have been exhausted. Overcoming the initial bronchospasm may improve tolerability.
File Format	HTM / HTML
ISSN	02770903
Issue Number	3
Volume Number	52
e-ISSN	15324303
Journal	Journal of Asthma
Language	English
Publisher	Taylor & Francis
Publisher Date	2015-04-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pulmonology Amphotericin B Therapeutic Use Antifungal Agents Aspergillosis, Allergic Bronchopulmonary Drug Therapy Epidemiology Asthma Adult Aged Administration & Dosage Adverse Effects Female Forced Expiratory Volume Humans Itraconazole Male Middle Aged Nebulizers And Vaporizers Quality Of Life Voriconazole Clinical Trial Journal Article
Content Type	Text
Resource Type	Article
Subject	Pulmonary and Respiratory Medicine Immunology and Allergy Pediatrics, Perinatology and Child Health

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Fungal Bronchitis and not allergic bronchopulmonary aspergillosis

Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.

Itraconazole as 'bridge therapy' to anti-IgE in a patient with severe asthma with fungal sensitisation.

Nebulised liposomal-amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis : a randomised, multicentre trial

The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis.

Use of Intravenous Pulse Steroids to Treat Allergic Bronchopulmonary Aspergillosis in a Non-Compliant Asthmatic Adolescent

Fungal bronchitis or allergic bronchopulmonary aspergillosis …that is the question

Efficacy of voriconazole in nonsurgical treatment of allergic and chronic granulomatous fungal rhinosinusitis: a preliminary study

Serologic allergic bronchopulmonary aspergillosis (ABPA-S): long-term outcomes.

Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA).

Similar Documents

Fungal Bronchitis and not allergic bronchopulmonary aspergillosis

Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.

Itraconazole as 'bridge therapy' to anti-IgE in a patient with severe asthma with fungal sensitisation.

Nebulised liposomal-amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis : a randomised, multicentre trial

The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis.

Use of Intravenous Pulse Steroids to Treat Allergic Bronchopulmonary Aspergillosis in a Non-Compliant Asthmatic Adolescent

Fungal bronchitis or allergic bronchopulmonary aspergillosis …that is the question

Efficacy of voriconazole in nonsurgical treatment of allergic and chronic granulomatous fungal rhinosinusitis: a preliminary study

Serologic allergic bronchopulmonary aspergillosis (ABPA-S): long-term outcomes.

Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA).